Blood-Based Biomarkers for Metabolic Syndrome

Trends in Endocrinology and Metabolism

Volumn 27, Issue 6, 2016, Pages 363-374

  O'Neill, Sadhbh ^a   Bohl, Mette ^b   Gregersen, Soren ^b   Hermansen, Kjeld ^b   O'Driscoll, Lorraine ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biomarkers; Exosomes; Extracellular vesicles; Metabolic syndrome; Nucleic acids; Proteins

Indexed keywords

BIOLOGICAL MARKER; DNA; MICRORNA; PROTEIN; RNA; NUCLEIC ACID;

BLOOD SAMPLING; CANCER RISK; CARDIOVASCULAR RISK; EXOSOME; HUMAN; MEMBRANE MICROPARTICLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; ANIMAL; METABOLISM;

ANIMALS; BIOMARKERS; EXOSOMES; EXTRACELLULAR VESICLES; HUMANS; METABOLIC SYNDROME; NUCLEIC ACIDS;

EID: 84963604320     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.03.012     Document Type: Review

References (52)

1. O'Neill S., O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes. Rev. 2015, 16:1-12.
2. Kaur J. A comprehensive review on metabolic syndrome. Cardiol. Res. Pract. 2014, 2014:943162.
3. Esposito K., et al. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care 2012, 35:2402-2411.
4. Nichols G.A., Moler E.J. Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes. Metab. Syndr. Relat. Disord. 2011, 9:127-133.
5. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013, 36:1033-1046. American Diabetes Association.
6. Heidenreich P.A., et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
7. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006, 113:2335-2362.
8. Pletcher M.J., Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation 2011, 123:1116-1124.
9. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definitions Working Group.
10. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 2013, 200:373-383.
11. Harding C., et al. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 1983, 97:329-339.
12. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33:967-978.
13. Lässer C. Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors. Exp. Opin. Biol. Ther. 2012, 12(Suppl. 1):S189-S197.
14. Borges F.T., et al. Extracellular vesicles: structure, function, and potential clinical uses in renal diseases. Braz. J. Med. Biol. Res. 2013, 46:824-830.
15. Van Deun J., et al. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. J. Extracell. Vesicles 2014, 3:24858.
16. Agouni A., et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am. J. Pathol. 2008, 173:1210-1219.
17. Agouni A., et al. Microparticles from patients with metabolic syndrome induce vascular hypo-reactivity via Fas/Fas-ligand pathway in mice. PLoS ONE 2011, 6:e27809.
18. Jensen S., et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 2011, 12:435-447.
19. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 2012, 13:239-250.
20. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
21. Karolina D.S., et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97:E2271-E2276.
22. Gallo A., et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS ONE 2012, 7:e30679.
23. Li L., et al. Argonaute 2 complexes selectively protect the circulating microRNAs in cell-secreted microvesicles. PLoS ONE 2012, 7:e46957.
24. Turchinovich A., et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39:7223-7233.
25. Arroyo J.D., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5003-5008.
26. Iwaki M., et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52:1655-1663.
27. Arita Y., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257:79-83.
28. Iwashima Y., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
29. Mohan V., et al. Association of low adiponectin levels with the metabolic syndrome -the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005, 54:476-481.
30. Ryo M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 2004, 68:975-981.
31. Halaas J.L., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543-546.
32. Esteghamati A., et al. Contribution of serum leptin to metabolic syndrome in obese and nonobese subjects. Arch. Med. Res. 2011, 42:244-251.
33. Mirza S., et al. Adiponectin/leptin ratio and metabolic syndrome in a Mexican American population. Clin. Invest. Med. 2011, 34:E290.
34. Gu H.F. Biomarkers of adiponectin: plasma protein variation and genomic DNA polymorphisms. Biomark. Insights 2009, 4:123-133.
35. Li P., et al. Correlation of serum adiponectin and adiponectin gene polymorphism with metabolic syndrome in Chinese adolescents. Eur. J. Clin. Nutr. 2015, 69:62-67.
36. Ohashi K., et al. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J. Am. Coll. Cardiol. 2004, 43:1195-1200.
37. Wang Y-T., et al. Circulating microRNAs have a sex-specific association with metabolic syndrome. J. Biomed. Sci. 2013, 20:72.
38. Lewis A.P., Jopling C.L. Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 2010, 38:1553-1557.
39. Fernandez-Hernando C., et al. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:178-185.
40. Gao W., et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 2012, 11:55.
41. Miura N., et al. Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. Clin. Med. Insights Oncol. 2008, 2:511-527.
42. Lihn A.S., et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol. Cell. Endocrinol. 2004, 219:9-15.
43. Standeven K.F., et al. Neprilysin, obesity and the metabolic syndrome. Int. J. Obes. 2011, 35:1031-1040.
44. von Lueder T.G., et al. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol. Ther. 2014, 144:41-49.
45. Rotllan N., Fernandez-Hernando C. MicroRNA regulation of cholesterol metabolism. Cholesterol 2012, 2012:847849.
46. Yamakuchi M. MicroRNA regulation of SIRT1. Front. Physiol. 2012, 3:68.
47. Davalos A., et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9232-9237.
48. Trajkovski M., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011, 474:649-653.
49. Esau C.C. Inhibition of microRNA with antisense oligonucleotides. Methods 2008, 44:55-60.
50. He H., et al. miR-204-5p promotes the adipogenic differentiation of human adipose-derived mesenchymal stem cells by modulating DVL3 expression and suppressing Wnt/beta-catenin signaling. Int. J. Mol. Med. 2015, 35:1587-1595.
51. McGregor R.A., Choi M.S. microRNAs in the regulation of adipogenesis and obesity. Curr. Mol. Med. 2011, 11:304-316.
52. Lee E.K., et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol. Cell. Biol. 2011, 31:626-638.